SIC
ENTA icon

SJS Investment Consulting’s Enanta Pharmaceuticals ENTA Stock Holding History

SJS Investment Consulting’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$13 – 2916
2026
Q1 		$13 Buy
+1
New +$13 ﹤0.01% 2406

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

SJS Investment Consulting's ENTA Position: Q2 2026 in Review

SJS Investment Consulting sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 1 share — an estimated $13 sold.

SJS Investment Consulting first reported a position in ENTA in Q1 2026 and held it in 1 quarter. The position peaked at $13 in Q1 2026. 51 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • SJS Investment Consulting reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 1 Enanta Pharmaceuticals share in Q2 2026, an estimated $13.
  • SJS Investment Consulting first reported a position in Enanta Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • SJS Investment Consulting's Enanta Pharmaceuticals position peaked at $13 in Q1 2026.
  • 51 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.